# Diabetes Research Hub — Monitor Report

**Run date:** 2026-07-02
**Previous monitor report:** monitor_report_2026-07-01.md
**Run type:** Automated review (read-only — no source files modified)

---

## TL;DR (what's actionable)

1. **GZR33 (GZR Bio) Phase 2/3 T2D trial flipped NOT_YET_RECRUITING → RECRUITING** (NCT07527078). Only status change in the trial set — worth a tracker note.
2. **2 new trials** appeared vs. yesterday (a ProGen GLP-1 switch study and a SAVA CGM device study); **3 dropped**. No new results posted.
3. **PubMed churn is high but low-signal:** 44 new / 51 dropped papers in 24h. Only 3 cross-domain papers, all reviews. The single most relevant new paper is a **CRISPR hypoimmune MSC-derived insulin-producing cell** review (bridges T1D Stem Cell Cure × Gene Therapy) — Tier 1-adjacent.
4. **Two significant regulatory/clinical events from earlier June are now well-reflected in the data** (Tzield pediatric expansion FDA approval June 12; generic dapagliflozin) — context, not new this week. Nothing genuinely broke in the last 7 days.
5. **Staleness flag:** gap analysis data is 2 days old (fine); but hub_monitor flags **767 result files >14 days old**. The gap *data* file (`literature_gap_data.json`) was last generated 2026-06-30 — current.

---

## File System Status

| File | Last modified | Status |
|------|--------------|--------|
| clinical_trials_latest.json | 2026-07-02 02:05 | Current (836 trials) |
| pubmed_recent_latest.json | 2026-07-02 02:06 | Current (161 unique papers, 30-day lookback) |
| hub_monitor_report.md | 2026-07-02 02:18 | Current |
| literature_gap_report.md | 2026-07-01 03:09 | Current |
| literature_gap_data.json | 2026-06-30 02:13 | Current (2 days) |
| Daily snapshots (CT + PubMed) | through 2026-07-02 | Present and continuous |

All five expected script outputs exist and are fresh. No missing files; no scripts need to be re-run to populate the hub.

**hub_monitor.py review flag:** 767 result files older than 14 days. Most of these are archived dated snapshots (`clinical_trials_snapshot_*`, `agent_state.json.bak_*`) that are *supposed* to be static — this is expected accumulation, not stale live data. No action required beyond optional cleanup of old `.bak` files.

---

## Clinical Trial Changes (2026-07-01 → 2026-07-02)

**Totals:** 836 trials tracked — 307 completed, 261 recruiting, 151 not-yet-recruiting, 110 active-not-recruiting, 7 enrolling-by-invitation. 308 have results posted.

**Status change (1):**
- **NCT07527078** — GZR33 Injection in T2D: `NOT_YET_RECRUITING → RECRUITING`. (GZR33 is a GLP-1/GIP-class candidate; now open for enrollment.)

**New trials (2):**
- **NCT07677891** — ProGen Co.: Phase 2, switching from dulaglutide to PG-102 (MG12) in T2D. *(NOT_YET_RECRUITING)*
- **NCT07679347** — SAVA Technologies: safety/performance of SAVA continuous glucose monitor. *(device, NOT_YET_RECRUITING)*

**Dropped trials (3):** NCT05812547, NCT06186102, NCT07408141 (removed from the active pull — likely completed/withdrawn/de-indexed; not investigated this run).

**New results posted:** 0.

### Key Phase 3 trials to keep watching (from key organizations)

| NCT | Sponsor | Therapy / focus | Status |
|-----|---------|-----------------|--------|
| NCT04786262 / NCT06832410 | Vertex | VX-880 (zimislecel) islet cell therapy, T1D | RECRUITING |
| NCT07222137 / NCT07222332 | Eli Lilly | Baricitinib — delay/preserve beta-cell function, T1D | RECRUITING |
| NCT07088068 | Sanofi | Teplizumab head-to-head, T1D | RECRUITING |
| NCT07076199 | Novo Nordisk | Insulin icodec (weekly), T1D | RECRUITING |
| NCT07564414 | Novo Nordisk | CagriSema dose-ranging | RECRUITING |
| NCT07613307 / NCT07668336 | Eli Lilly | Orforglipron (oral GLP-1) | NOT_YET_RECRUITING |
| NCT06260722 / NCT06297603 | Eli Lilly | Retatrutide (triple agonist) | ACTIVE_NOT_RECRUITING |

48 Phase 3 trials are currently recruiting overall. Notable non-key-org Phase 3: vTv's cadisegliatin (glucokinase activator, T1D adjunct, NCT06334133) — relevant to the Glucokinase gap cluster below.

---

## PubMed Highlights (last 24h delta)

**Volume:** 161 unique papers over the 30-day window; +44 / −51 vs. yesterday. Most active domains: Diabetes AI/ML (188 total hits), T2D GLP-1 New (170), Diabetes Microbiome (164), Diabetes Biomarker (123).

**Low/no-activity flag:** `GLP-1 Pharmacogenomics` returned **0 papers** — likely a query/terminology issue in `baseline_pubmed_alerts.py` rather than a true absence. Worth verifying the search string.

**Cross-domain papers (highest value — 3 new):**
- **[42387220]** *Overcoming Immunological Barriers in MSC-Derived Insulin-Producing Cells through CRISPR-Based Hypoimmune [engineering]* — T1D Stem Cell Cure × Gene Therapy. **Most relevant to our Tier 1 work.**
- **[42387035]** *Tirzepatide as a multi-organ integrator in metabolic diseases* (review) — T2D GLP-1 × Microbiome.
- **[42385762]** *Global/regional burden of TB and MDR-TB by HIV status* — Biomarker × Health Equity (tangential; likely keyword overlap, not core).

**Key-therapy mentions (30-day):** teplizumab 7, orforglipron 10, retatrutide 5, CagriSema 5, baricitinib 4, icodec 4, **dapagliflozin 53** (spike consistent with the generic-approval news cycle). **zimislecel: 0** — despite Vertex Phase 3 activity, no new indexed papers; monitor for the naming variant "VX-880."

---

## Gap Analysis Summary (generated 2026-06-30)

Top under-researched intersections (Gap Score 100, BRONZE confidence — single analytical source, expert confirmation required):

1. **Beta Cell Regen × Health Equity** — 0 joint pubs. Who gets access to regenerative therapies is unstudied.
2. **Insulin Resistance × Islet Transplant** — 1 joint pub. IR in graft recipients affects survival; barely examined.
3. **Islet Transplant × Drug Repurposing** — 0 joint pubs. Existing immunosuppressants unscreened for islet protection.
4. **Islet Transplant × Health Equity** — 0 joint pubs. Access to select-center-only therapy unexamined.
5. **Gene Therapy × LADA** — 0 joint pubs. Autoimmune mechanism makes LADA a gene-therapy candidate; no crossover.

**Alignment with Tier 1 doctrine areas:**
- Gaps #3 (Islet Transplant × **Drug Repurposing**) and the Glucokinase × Drug Repurposing gap map directly onto **Tier 1 #4 (Drug Repurposing Computational Screening)** — actionable with OpenTargets/STRING/DrugBank, no data-access barrier.
- Gaps #1 and #4 (Health Equity intersections) map onto **Tier 1 #6 (Epidemiological / Health Equity analysis)** — publicly available GBD/IDF/CDC data.
- The new CRISPR-MSC paper [42387220] sits at the Multi-Omics / Gene Therapy edge relevant to **Tier 1 #1 and #2**.

The gap analysis and the day's literature are consistent: islet transplant (247 total pubs since 2020) remains the lowest-volume, highest-gap domain and the strongest candidate for cross-domain computational contribution.

---

## Breaking News (web check, last ~7 days)

Nothing genuinely new broke in the past 7 days. The two significant recent events are from **early-to-mid June** and are already reflected in the hub's data:

- **FDA accelerated approval — Tzield (teplizumab) pediatric expansion** (June 12, 2026): delays insulin-production decline in children 8–17 with recently diagnosed Stage 3 T1D. First approval for this indication. Consistent with the teplizumab Phase 3 activity (NCT07088068) and 7 PubMed mentions.
- **First generic dapagliflozin approved** (June 2026): expands SGLT2i access, incl. HF-hospitalization-risk reduction in T2D. Explains the dapagliflozin mention spike (53).
- **Retatrutide first Phase 3 T2D/obesity results** (ADA, June 6): HbA1c ↓ up to 2.0%, weight ↓ up to 16.8% at 40 weeks. Context for the ACTIVE_NOT_RECRUITING retatrutide Phase 3 set.

Evidence level for these: press-release / conference-presentation stage (SILVER at best pending peer-reviewed publication per the Research Doctrine). No FDA action or Phase 3 readout dated within the last 7 days was found.

Sources:
- [FDA — Tzield pediatric approval](https://www.fda.gov/news-events/press-announcements/fda-approves-new-indication-tzield-teplizumab-certain-pediatric-patients-recently-diagnosed-stage-3)
- [AJMC — first generic dapagliflozin](https://www.ajmc.com/view/fda-approves-first-generic-dapagliflozin-to-reduce-hf-hospitalization-risk-in-type-2-diabetes)
- [ADA — retatrutide triple-hormone Phase 3](https://diabetes.org/newsroom/press-releases/breakthrough-studies-demonstrate-effectiveness-first-triple-hormone-therapy)

---

## Recommended Actions

1. **Update the tracker** with the GZR33 status flip (NCT07527078 → RECRUITING) and the two new trials (NCT07677891, NCT07679347).
2. **Review cross-domain paper [42387220]** (CRISPR hypoimmune MSC-derived insulin-producing cells) — relevant to Tier 1 Multi-Omics/Gene Therapy and the Beta Cell Regen domain. Pull full text into `paper_library/`.
3. **Fix the `GLP-1 Pharmacogenomics` PubMed query** in `baseline_pubmed_alerts.py` — 0 hits is almost certainly a bad search string, not a real gap.
4. **Optional cleanup:** 767 files flagged >14 days old are mostly static snapshots and `.bak` files. Consider archiving `agent_state.json.bak_*` older than 30 days to reduce noise in the staleness flag.
5. **No script re-runs needed** — all five data sources are current (≤2 days). Gap analysis is fine until ~2026-07-07; re-run `project1_literature_gap_analysis.py` if you want it inside a 7-day window.
6. **Investigate the 3 dropped trials** (NCT05812547, NCT06186102, NCT07408141) only if tracker integrity matters — likely benign de-indexing.

---

*Generated by the automated Diabetes Hub Monitor. Read-only review — no existing files were modified. All new claims labeled with evidence levels per RESEARCH_DOCTRINE.md; trial/paper findings are BRONZE pending verification against primary sources.*
